CMS home health rule lifts 2027 pay 2.4% and makes every Medicare revocation retroactive
Home health agencies get an estimated $415 million more in 2027 despite a second 3% temporary cut, and the same rule lets CMS date enrollment revocations for Medicare providers back to when noncompliance began.

The rule that sets Medicare's 2027 home health rates reaches well past home health agencies. Alongside a raise for agencies, it gives the Centers for Medicare & Medicaid Services more power to recover money from Medicare providers and suppliers of every type.
CMS issued the final rule Nov. 4, estimating that Medicare's payments to home health agencies in 2027 will rise 2.4%, or $415 million, compared with 2026, according to the agency's fact sheet. That combines a 2.1% payment update worth $365 million with an estimated 0.3% increase, worth $50 million, from an updated outlier threshold.
Why it matters: For home health agencies, the increase comes with a second straight 3% temporary cut to the base rate as CMS keeps recovering what it calculates as past overpayments. For other Medicare providers and suppliers, the rule makes every ground for revoking enrollment retroactive to when noncompliance began and adds new grounds for denial and revocation. CMS estimated the enrollment changes will save taxpayers about $82 million a year.
The overpayment math
Medicare moved home health to the Patient-Driven Groupings Model and a 30-day unit of payment on Jan. 1, 2020, under the Bipartisan Budget Act of 2018. The law required CMS to assume how agencies' behavior would change, compare that with what actually happened, and adjust rates to keep the switch budget neutral.
CMS has already applied permanent cuts of 3.925% in 2023, 2.890% in 2024 and 1.975% in 2025, each half of the adjustment it estimated at the time, then applied the remaining 1.023% for 2020 through 2022 behavior in 2026. It also began recovering past overpayments that year with a temporary 3% reduction. The 2027 rule repeats that 3% temporary cut to keep recouping overpayments from 2020 through 2025.
CMS did not propose a new permanent cut, saying behavior changes in preliminary 2025 claims may not stem directly from the payment model. The agency said taking the temporary recovery in steps may reduce the need for a large cut later.
The rule also recalibrates case-mix weights and low-utilization payment thresholds for the model's 432 payment groups using 2025 data.
Beyond the rates
Today some revocations take effect 30 days after CMS mails notice, while others reach back to the start of the noncompliance. The final rule makes all of them retroactive, which CMS said will help it recover money paid to noncompliant providers. Most of the rule's enrollment provisions apply to all Medicare provider types, according to the fact sheet.
New grounds for denial or revocation include some misdemeanor convictions for financial misconduct or sexual assault, and enrollments CMS judges to carry a high fraud risk because too many providers are clustered in a small geographic area, according to the press release. CMS said it will weigh the facts of each case.
Hospices, home health agencies and suppliers of durable medical equipment, prosthetics, orthotics and supplies must reenroll as new providers, including a survey or accreditation, after certain changes in majority ownership.
CMS said Medicare's current home health benefit can pay for skilled palliative care for eligible patients, such as pain and symptom management at home, and plans to issue examples in later guidance. The agency said the clarification addresses provider uncertainty and is not a new benefit.
Agencies will have 45 days, down from 135, to submit Outcome and Assessment Information Set data, which CMS said will make quality information public up to three months sooner. About 98% of agencies already meet the 45-day window, the agency said.
Starting April 1, 2027, the durable medical equipment benefit will cover some external infusion pumps and the home infusion drugs used with them under a provision of the Consolidated Appropriations Act, 2026. Among the conditions, the drug's FDA-approved prescribing information must call for administration by or under the supervision of a health care professional, and for infusion at least 12 times a year, either intravenously or subcutaneously or at rates that require an external pump. CMS adopted the 12-times-a-year test in place of the once-a-month standard it had proposed.
The rule was published in the Federal Register on Nov. 9. CMS said it will continue its annual analysis, through 2026 claims, to decide whether more permanent adjustments are needed.



